Background:x3A4;o evaluate the predictive value of genes involved in resistance to platinum-taxane chemotherapy in patients ith epithelial ovarian cancer  EOC . Material and Methods: Microdissected formalin-fixed tumoral samples from 187 EOC patients primary tumors ere analyzed. Ninety samples correspond to the experimental and ninety seven to the validation set, and patients ere matched in clinical characteristics and pathological features. All specimens ere analyzed for ATP7b, BRCA1, BRCA2, PARP1, RAP80, HOXA9, DAXX, THIOREDOXIN-1, TSP1, TXR1 mRNA expression by quantitative real-time PCR. Most of the patients  172 out of 187  received carboplatin-paclitaxel regimen. Expression levels ere correlated ith overall survival  OS  and progression free survival  PFS  by multivariate analysis. Results: Patients ith high THIOREDOXIN-1 and TSP1 expression presented longer PFS  p = 0.001 and p lt 0.001, respectively  and OS  p = 0.024 and p lt 0.001, respectively . High TXR1 expression as associated ith decreased PFS  p lt 0.001  and OS  p lt 0.001 . Multivariate analysis demonstrated that high TXR1lo TSP1 expression as an independent factor for decreased PFS  HR 1.94; 95 percent CI 1.482.92; p = 0.008  and OS  HR 3.89; 95 percent CI 2.166.87; p lt 0.001 , hereas lo THIOREDOXIN-1 expression as correlated ith decreased PFS  HR 1.44; 95 percent CI 1.052.84; p = 0.043  and OS  HR 2.38; 95 percent CI 1.782.77; p = 0.009 . Conclusions: These findings indicate that TXR1TSP1 and THIOREDOXIN-1 expression could be used for the prediction of resistance to treatment of EOC patients and, therefore merit to be further evaluated.,J Clin Oncol 34, 2016  suppl; abstr e17086 ,Publication Only Gynecologic Cancer